SynOx Therapeutics
PrivateLast Round
Series B
Extension
Oct 30, 2024
Total Funding Raised
$135.7M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SynOx Therapeutics is a biotechnology company developing emactuzumab, a monoclonal antibody, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other macrophage-driven disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SynOx Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
SynOx Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Oct 30, 2024 | ||||
| Series B | Apr 22, 2024 | ||||
| Series A | Nov 19, 2020 |
Key People
Founding team and executive leadership
SynOx Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B Extension, Series A, Series B |
| Gimv | Series A |
| Gilde Healthcare | Series B Extension |
| HealthCap | Series B Extension, Series B, Series A |
| Bioqube Ventures | Series B Extension, Series B |
| Medicxi | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors grew 86% MoM, from 753 to 1.4K.
- Feb 17, 2026
Grew 22% QoQ from 23 to 28 employees.
SynOx Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SynOx Therapeutics's valuation, stock price, and market status.